Background
Advances in antiretroviral drugs (ARVs) have prevented gestational human immunodeficiency virus type 1 (HIV-1) transmission from mother to fetus. This is reflected in the rising numbers of HIV-1-exposed uninfected (HEU) children. Worldwide, the number of HEU children exceeds sixteen million, with more than one million children added to this group yearly. Although HEU children remain uninfected, they are at an increased risk of neurodevelopmental deficits. Notably, in utero exposure to ARVs is a potential causative factor, warranting close monitoring and therapeutic intervention. We now demonstrate that long-acting (LA) injectable can be used to successfully mitigate in utero ARV-exposure-associated embryo brain metabolomic dysregulations in a mouse model.
Methods
Pregnant C3H/HeJ mice (dams) were treated orally every day with dolutegravir (DTG) at a human equivalent dosage (5 mg/kg/day) or vehicle (control). These were compared against dams injected with a single intramuscular (IM) nanoformulated DTG (NDTG) at 45 mg/kg. Treatment was initiated at gestation day (GD) 0.5 for all groups. DTG levels were measured in plasma of dams and whole brain tissues of embryos at GD 17.5 using mass spectrometry. CEST MRI was performed on embryo brains at GD 17.5 to confirm effects on embryo brain metabolites.
Results
A single IM injection of NDTG or daily oral DTG administration achieved equivalent therapeutic plasma DTG levels (1,400-2,500 ng/mL) in pregnant dams. However, three-fold lower DTG levels were observed in the embryo brain following NDTG injection. For daily oral DTG, average concentrations of 97.4 ng/g were recorded compared to 29 ng/g for a single IM injection of NDTG. CEST hyperintensities at -3.5 ppm (nuclear Overhauser effect) and 3.5 ppm (amide/amine protons) were measured in the embryo brains exposed to DTG. These reflect DTG-induced altered cellular membrane lipids, mobile proteins or peptides, and glutamate levels, signifying impaired neuronal development. Whereas comparative CEST contrasts at -3.5 and 3.5 ppm were noted between control and NDTG-treated groups, indicating prevention of DTG-induced metabolomic changes when delivered as NDTG.
Conclusions
CEST MRI detects DTG-induced changes in fetal neurometabolome and benefits of NDTG in attenuating those adverse events. These data, taken together, demonstrate therapeutic benefits of LA injectable delivery of ARVs in mitigating neurodevelopmental impairments by limiting drug exposure to the embryo brain.
Table or Figure
